Standard BioTools

Standard BioTools Deferred Tax Liabilities

The Deferred Tax Liabilities of Standard BioTools (LAB) as of Nov 2, 2026 is 1.08 M USD. In the previous year, Deferred Tax Liabilities was 840,000.00 USD — a change of 28.57% (higher).

Deferred Tax Liabilities

1.08 MUSD

YoY

28.57%

Last updated:

Deferred Tax Liabilities of Standard BioTools is 2024 1.08 M USD. Deferred Tax Liabilities of Standard BioTools was 2023 840,000.00 USD. It decreases by 28.57% higher compared to the previous year.

The Standard BioTools Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2017
16.90 M USD
Jan 1, 2018
13.70 M USD
Jan 1, 2019
11.50 M USD
Jan 1, 2020
8.70 M USD
Jan 1, 2021
4.30 M USD
Jan 1, 2022
1.10 M USD
Jan 1, 2023
840,000.00 USD
Jan 1, 2024
1.08 M USD
The Standard BioTools Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
1.08 MUSD+28.57%
840,000.00USD-23.64%
1.10 MUSD-74.42%
4.30 MUSD-50.57%
8.70 MUSD-24.35%
11.50 MUSD-16.06%
13.70 MUSD-18.93%
16.90 MUSD-19.91%
21.10 MUSD-10.59%
23.60 MUSD-9.92%
26.20 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Deferred Tax Liabilities of Standard BioTools is 1.08 M USD in 2024.

Deferred Tax Liabilities of Standard BioTools changed from 840,000.00 USD to 1.08 M USD, representing a 28.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools